• 1. Aggregation-induced emission enhancement of carbon quantum dots and applications in light emitting devices
  Rongyan Guo,Tao Li,Shuie Shi J. Mater. Chem. C, 2019,7, 5148-5154
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An ATP-selective, lanthanide complex luminescent probe?
  Xiao Liu,Jun Xu,Yinyun Lv,Wenyu Wu,Weisheng Liu,Yu Tang Dalton Trans., 2013,42, 9840-9846
• 4. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Research Briefing on 1-(3-cyclopentylpropyl)piperazine (CAS: 827614-49-3) in Chemical Biology and Pharmaceutical Applications

1-(3-cyclopentylpropyl)piperazine (CAS: 827614-49-3) is a chemical compound that has garnered significant attention in recent pharmaceutical and chemical biology research due to its potential therapeutic applications. This compound, characterized by its piperazine core and cyclopentylpropyl side chain, has been explored for its role in modulating various biological targets, including neurotransmitter receptors and enzymes involved in disease pathways. Recent studies have highlighted its utility in drug discovery, particularly in the development of novel central nervous system (CNS) agents and antimicrobial compounds.

One of the key areas of investigation for 1-(3-cyclopentylpropyl)piperazine is its interaction with serotonin and dopamine receptors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit high affinity for 5-HT_1A and D₂ receptors, suggesting potential applications in treating psychiatric disorders such as schizophrenia and depression. The study utilized molecular docking and in vitro binding assays to elucidate the structural determinants of receptor binding, providing a foundation for further optimization of this scaffold.

In addition to its CNS applications, 1-(3-cyclopentylpropyl)piperazine has shown promise in antimicrobial research. A recent preprint on bioRxiv reported that this compound, when conjugated with other pharmacophores, exhibits potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The mechanism of action appears to involve disruption of bacterial cell membrane integrity, as evidenced by electron microscopy and fluorescence-based assays. These findings open new avenues for the development of next-generation antibiotics.

The synthesis and scalability of 1-(3-cyclopentylpropyl)piperazine have also been addressed in recent literature. A 2024 paper in Organic Process Research & Development detailed a novel, cost-effective synthetic route for this compound, achieving a 78% yield with minimal byproducts. This advancement is critical for enabling large-scale production and further preclinical evaluation. The paper also highlighted the compound's stability under various storage conditions, which is a key consideration for pharmaceutical development.

Despite these promising developments, challenges remain in the clinical translation of 1-(3-cyclopentylpropyl)piperazine-based therapeutics. Pharmacokinetic studies in animal models have revealed variable bioavailability, prompting ongoing research into prodrug strategies and formulation optimization. Furthermore, the compound's off-target effects on other receptor subtypes necessitate careful structure-activity relationship (SAR) studies to improve selectivity. These gaps present opportunities for interdisciplinary collaboration between chemists, biologists, and pharmacologists.

In conclusion, 1-(3-cyclopentylpropyl)piperazine (CAS: 827614-49-3) represents a versatile scaffold with broad potential in drug discovery. Its applications span CNS disorders, infectious diseases, and beyond, supported by a growing body of preclinical evidence. Future research should focus on addressing the current limitations while exploring new therapeutic indications for this promising compound.

• 8005-33-2(1-(3-Cyclohexylpropyl)piperazine)
• 57184-45-9(1-(3-methylpentyl)piperazine)
• 132800-12-5(1-(2-Cyclohexylethyl)piperazine)
• 800372-97-8(1-(3-Cyclohexylprop-1-yl)piperazine)
• 774477-60-0(3-Azabicyclo[4.2.1]nonane-3-ethanamine)
• 5472-60-6( )
• 1048649-04-2(1-(Cyclopentylmethyl)piperazine dihydrochloride)
• 775288-46-5(1-methyl-4-[2-(piperidin-4-yl)ethyl]piperazine)
• 82500-22-9(1-(Cyclopentylmethyl)piperazine)
• 1215167-72-8(1-(Cyclopentylmethyl)piperazine hydrochloride)